en · de · es · pt
cjc-1295-notes.peptides3081.com › Data › Handling Storage And Quality Control — Common Mistakes

Handling Storage And Quality Control — Common Mistakes

By Editorial Desk · published 2026-02-05 · last reviewed 2026-03-09 · Data

GHRH analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-03-09 and is reviewed periodically as new material appears.

Handling Storage and Quality Control

Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.

Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.

Background and Naming Conventions

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.

The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.

Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.

Cjc-1295 at a glance

PropertyValueNotes
Purity assessmentReverse-phase HPLCReported as area percentage
Identity confirmationMass spectrometryElectrospray or laser desorption
Powder storageMinus 20 degrees Celsius or lowerDark and dry conditions
Solution storageTwo to eight degrees CelsiusAvoid repeated freeze-thaw
AppearanceWhite to off-white powderCommon lyophilized form

Compound Identity and Development History

The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.

Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.

Related pages on this site

Analytical Characterization and Storage

Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.

Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.

Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.

Background and Molecular Features

CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.

Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.

The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.

Identity and Naming History

CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.

The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.

Supporting material

== Uses == Synthetic platelets have diverse therapeutic applications, including treating hemostasis in trauma care, clotting disorders, and immune responses in conditions such as thrombosis, inflammation, and cancer. Originally researched to replicate the biochemistry and cell and molecular biology of natural platelets, platelet-mimicking particles are now in preclinical development for multiple therapeutic applications with specialized drug delivery mechanisms. The need for these particles is informed by increasing rates of reported thrombocytopenia cases and clinical bleeding syndrome diagnoses such as von Willebrand disease or Glanzmann thrombasthenia. Early treatment solutions of the mid-late twentieth century were not based upon current findings in nanoparticle drug delivery technologies, thus lacking the ability to overcome primary limitations of natural platelets. With a diverse assortment of platelet-mimicking particle formulations under testing, their use can be widespread to multiple clinical diagnoses and areas—antimicrobial platelets, cancer, hemorrhage and trauma, bleeding disorders, and cholesterol clearance.

7α-Acetylthio-17α-hydroxy-3-oxopregn-4-ene-21-carboxylic acid γ-lactone 7α-Acetylthio-3-oxo-17α-pregn-4-ene-21,17β-carbolactone 3-(3-Oxo-7α-acetylthio-17β-hydroxyandrost-4-en-17α-yl)propionic acid lactone 7α-Acetylthio-17α-(2-carboxyethyl)androst-4-en-17β-ol-3-one γ-lactone 7α-Acetylthio-17α-(2-carboxyethyl)testosterone γ-lactone

=== 14 May === Russian missiles struck Ternopil Oblast, causing damage to civilian property. The Russian military claimed to have launched strikes on deployment points of Ukrainian forces and arms depots in the oblast as well as in Petropavlivka in Dnipropetrovsk Oblast. The Governor of Russia's Bryansk Oblast said a Ukrainian drone attack damaged a food processing facility in Starodub. The Russian Ministry of Defence confirmed the death of Colonels Vyacheslav Makarov and Yevgeny Brovko of the 4th Motorized Rifle Brigade during fighting in Bakhmut. The Russian military said it had repelled Ukrainian attacks in the north and south of Bakhmut while Yevgeny Prigozhin, head of the Wagner Group said his forces had advanced up to 130 metres (430 ft) over the past 24 hours. He also claimed control over 28 multi-story buildings in western districts of Bakhmut and estimated Ukrainian forces were still holding 20 buildings and a total area of 1.69 square km (0.65 square miles). Meanwhile, the Ukrainian Defence Ministry said its forces captured more than ten enemy positions in the north and south of Bakhmut and cleared a large area of forest near Ivanivske. The Washington Post, citing leaked documents from the Pentagon, reported that Prigozhin secretly contacted Ukrainian intelligence in January 2023 to reveal Russian military positions in exchange for a Ukrainian withdrawal from Bakhmut, which was refused, and advised them to advance towards Crimea while informing them of shortages in Russian ammunition.

Sources: en.wikipedia.org

Supporting material

Ptosis or sagging of the female breast is a natural consequence of aging. The rate at which a woman's breasts drop and the degree of ptosis depends on many factors. The key factors influencing breast ptosis over a woman's lifetime are cigarette smoking, her number of pregnancies, higher body mass index, larger bra cup size, and significant weight change. Post-menopausal women or people with collagen deficiencies may experience increased ptosis due to a loss of skin elasticity. Many women and medical professionals mistakenly believe that breastfeeding increases sagging. It is also commonly believed that the breast itself offers insufficient support and that wearing a bra prevents sagging, which has not been found to be true. Plastic surgeons categorize the degree of ptosis by evaluating the position of the nipple relative to the infra-mammary fold, the point at which the underside of the breasts attach to the chest wall. In the most advanced stage, the nipples are below the fold and point toward the ground. Women's breasts undergo changes in size, volume, and position throughout their lives. In young women with large breasts—or even breast hypertrophy—sagging can occur early on due to the effects of gravity. The primary cause is often a disproportion between breast volume/weight and body size.

The prevailing academic opinion is that the Israelites were a mixture of peoples predominately indigenous to Canaan, with additional input from an Egyptian matrix of peoples, which most likely inspired the Exodus narrative. Israel's demographics were similar to the demographics of Ammon, Edom, Moab and Phoenicia. Israelite cultural identity was defined by a sense of a shared memory of a collective past in the story of Exodus. Cultural boundaries were marked by ritual practices involving body, food, and time, including male circumcision, avoidance of pork consumption and marking time based on the Exodus, the reigns of Israelite kings, and Sabbath observance. The first two practices were observed by neighbouring west Semites besides the Philistines, who were of Mycenaean Greek origin. As a result, intermarriage with other Semites was common. But what distinguished Israelite circumcision from non-Israelite circumcision was its emphasis on 'correct' timing. Israelite circumcision also served as a mnemonic sign for the circumcised, where their 'unnatural' erect circumcised penis would remind them to behave differently in sexual matters. Yom-Tov Lipmann-Muhlhausen suggests that Israelite identity was based on faith and adherence to sex-appropriate commandments. For men, it was circumcision. For women, it was ritual (animal) sacrifice after childbirth (Leviticus 12:6).

Pat Wing I (パトウィング1, Pato Wingu Wan): Deka Red's personal fighter jet–themed Pat Wing that forms the head, torso, and upper legs of Deka Wing Robo. It also possesses the highest speed and mobility. Pat Wing II (パトウィング2, Pato Wingu Tsū): Deka Blue's personal VTOL-themed Pat Wing that forms the arms of Deka Wing Robo. It also possesses hovering capabilities, high stability, and wingtip blasters. Pat Wing III (パトウィング3, Pato Wingu Surī): Deka Green's personal cargo jet–themed Pat Wing that forms the lower legs of Deka Wing Robo. It is also highly confidential, making it suitable for the conveyance of dangerous goods. Pat Wing IV (パトウィング4, Pato Wingu Fō): Deka Yellow's personal stealth bomber–themed Pat Wing that forms the right foot of Deka Wing Robo. It also possesses high stealth and endurance capabilities, and is equipped with special arms such as flares and tear gas bombs. Pat Wing V (パトウィング5, Pato Wingu Faibu): Deka Pink's personal water bomber–themed Pat Wing that forms the left foot of Deka Wing Robo. It is also equipped with a speaker and fire-extinguishing capabilities.

==== Plans to sell TikTok's US operations ==== Since at least 2020, following calls to ban TikTok in the country, the Committee on Foreign Investment in the United States (CFIUS) has been investigating the company's 2017 merger with Musical.ly but has not finalized any of its negotiations with TikTok, such as the Project Texas proposal, waiting instead for Congress to act. In January 2025, Chinese officials began preliminary talks about potentially selling TikTok's US operations to Elon Musk if the app faced an impending ban due to national security concerns. While Beijing preferred TikTok remain under ByteDance's control, the sale could happen through a competitive process or with US government involvement. One possibility involved Musk's platform, X, taking over TikTok's US business. The move came ahead of a Supreme Court case that upheld the constitutionality of a law that would force a sale or ban of TikTok in the US by 19 January 2025, due to national security concerns regarding its ties to China. Other potential buyers included Project Liberty's "The People's Bid For TikTok" consortium of Frank McCourt with Kevin O'Leary, Steven Mnuchin, and Bobby Kotick, and an investor consortium led by Employer.com founder Jesse Tinsley that included Roblox CEO David Baszucki and YouTuber MrBeast and claimed to have secured over US$20 billion in commitments. The seriousness of these potential buyers was unclear. The day before the impending ban, California-based conversational search engine company Perplexity AI submitted a bid for a merger with TikTok US.

Sources: en.wikipedia.org

Supporting material

HATU (Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium) is a reagent used in peptide coupling chemistry to generate an active ester from a carboxylic acid. HATU is used along with Hünig's base (N,N-diisopropylethylamine), or triethylamine to form amide bonds. Typically dimethylformamide is used as solvent, although other polar aprotic solvents can also be used.

== Ligand variations == Since the initial MPAA ligand report, many variations of bifunctional ligands derived from amino acids have been developed. Bidentate MPAQ (mono-protected amino quinoline) ligands were introduced in the application of β-methylene C–H bonds in aliphatic amides. The highly successful MPAO (mono-protected amino oxazoline) ligand allowed for C(sp3)–H functionalization via arylation of α-methyls, borylation of cyclobutyl carboxylic amides, and boronic cross coupling of alkyl amines. MPAAM (mono-protected aminoalkyl amine) ligands were used in enantioselective C(sp3)–H arylations of free aliphatic acids without the need for exogenous directing groups. Variations of the MPAAThio (mono-protected aminoalkyl thioether) ligands have been use in olefination of free carboxylic acids and arylation, carbonylation, and olefination of free aliphatic amines. Expanding the reaction substrate scope to non-directed C(sp2)–H bonds, pyridone ligands were developed to functionalize arenes and heteroarenes which proved to be particularly useful in late-state derivatization of bioactive compounds such as estrone, caffeine, and camptothecin. Many analogues of the pyridine-pyridone (azine-pyridone) ligands were developed and used in the C(sp2)–H hydroxylation of (hetero)arenes and the dehydrogenation of methylene C(sp3)–H bonds on alkyl free acids.

=== Financing === In May 2016, Cerebras raised $27 million in a series A round led by Benchmark, Foundation Capital and Eclipse Ventures. In December 2016, the company raised a series B round led by Coatue Management. In January 2017, it raised a series C round led by VY Capital. In November 2018, Cerebras raised $88 million in a series D round, making the company a unicorn. Investors in this round included Altimeter, VY Capital, Coatue, Foundation Capital, Benchmark, and Eclipse. In November 2019, Cerebras raised $270 million in a series E round at a valuation of $2.4 billion. In November 2021, Cerebras raised $250 million in a Series F round, valuing the company at over $4 billion and bringing its total financing to $720 million. The Series F financing round was led by Alpha Wave Ventures and Abu Dhabi Growth Fund (ADG). In July, August, and September 2024, the company raised $85 million in a series F-1 round, selling shares for $14.66 each. In September 2025, the company raised $1.1 billion in a Series G round, selling shares for $36.23 each, or a valuation of $8.1 billion. In January 2026, the company raised $1.0 billion in a Series H round, selling shares for $89.01 each. In this round, Benchmark invested $225 million, while Alpha Wave and funds managed by Fidelity Investments each invested $100 million. On May 14, 2026, the company became a public company via the largest U.S. technology initial public offering since 2019, raising $5.55 billion by selling 30 million shares at $185 each and opening on Nasdaq at $350, valuing the company at $95 billion.

Sources: en.wikipedia.org

Frequently asked questions

How should the lyophilized powder be stored?

The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.

Which methods confirm identity and purity?

Reverse-phase high-performance liquid chromatography is used for purity. Mass spectrometry confirms molecular weight and sequence integrity. Amino acid analysis offers an additional compositional check.

How long do reconstituted solutions remain stable?

Published stability data for dissolved material are limited and vary with conditions. Refrigerated solutions are generally used within a short period. The exact shelf life depends on concentration, buffer, and handling.

Does this compound occur naturally in the body?

No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.

Network